Pomalyst

Bristol Myers snags Pomalyst green light in rare AIDS-related skin lesions
Bristol Myers snags Pomalyst green light in rare AIDS-related skin lesions
Fierce Pharma
Bristol-Myers Squibb
Pomalyst
AIDS
FDA
Kaposi's Sarcoma
Flag link:
Celgene gets FDA breakthrough therapy designation for Pomalyst to treat Kaposi sarcoma
Celgene gets FDA breakthrough therapy designation for Pomalyst to treat Kaposi sarcoma
Pharmaceutical Business Review
Celgene
Pomalyst
breakthrough therapies
Kaposi's Sarcoma
Flag link:
Bristol-Myers Squibb snags quick Empliciti combo nod in multiple myeloma
Bristol-Myers Squibb snags quick Empliciti combo nod in multiple myeloma
Fierce Pharma
Bristol-Myers Squibb
AbbVie
Empliciti
FDA
Multiple Myeloma
Celgene
Pomalyst
Flag link:
Bristol-Myers (BMY) sBLA for Empliciti Gets Priority Review
Bristol-Myers (BMY) sBLA for Empliciti Gets Priority Review
Yahoo/Zacks.com
Bristol-Myers Squibb
Empliciti
Celgene
Pomalyst
Multiple Myeloma
Flag link:
With Revlimid and Pomalyst price increases, could Celgene be next on Trump’s to-call list?
With Revlimid and Pomalyst price increases, could Celgene be next on Trump’s to-call list?
Fierce Pharma
Pfizer
Celgene
drug pricing
Donald Trump
Revlimid
Pomalyst
Flag link:
Looking to grow blockbuster Pomalyst franchise, Celgene declares a win for multiple myeloma triplet in pivotal PhIII
Looking to grow blockbuster Pomalyst franchise, Celgene declares a win for multiple myeloma triplet in pivotal PhIII
Endpoints
Celgene
Pomalyst
Multiple Myeloma
clinical trials
Flag link:
Celgene takes its most aggressive price hikes yet on Revlimid, Pomalyst: analyst
Celgene takes its most aggressive price hikes yet on Revlimid, Pomalyst: analyst
Fierce Pharma
Celgene
Revlimid
Pomalyst
drug pricing
Flag link:
5 Reasons Celgene Will Be a Top Biotech Stock for the Next Decade
5 Reasons Celgene Will Be a Top Biotech Stock for the Next Decade
Motley Fool
Celgene
Revlimid
Pomalyst
Abraxane
Otezla
Flag link:
Celgene's Fastest-Growing Drugs
Celgene's Fastest-Growing Drugs
Motley Fool
Celgene
Otezla
Pomalyst
Flag link:
What's Next For Celgene
What's Next For Celgene
Motley Fool
Celgene
JPMHC 2017
Otezla
ozanimod
Revlimid
Pomalyst
Flag link:
New Merck Study Shows Combos Will Drive Celgene Growth: RBC
New Merck Study Shows Combos Will Drive Celgene Growth: RBC
Barron's
Merck
Celgene
Pomalyst
Flag link:
The top 10 most expensive drugs of 2013
The top 10 most expensive drugs of 2013
Fierce Pharma
drug pricing
Soliris
Alexion
Naglazyme
Biomarin
Kalydeco
Vertex
Cinryze
Shire
Sprycel
Bristol-Myers Squibb
Pomalyst
Celgene
Xyrem
Jazz Pharmaceuticals
Erbitux
Merck KGaA
Revlimid
Questcor
Mallinckrodt
H.P. Acthar Gel
Flag link:
Analysis of FDA side-effect reports flags Sanofi, Celgene meds
Analysis of FDA side-effect reports flags Sanofi, Celgene meds
Fierce Pharma
Celegene
FDA
Sanofi
side effects
Pomalyst
Tecfidera
Biogen Idec
Aubagio
Flag link:
Celgene's New Multiple Myeloma Drug Is Beating Amgen
Celgene's New Multiple Myeloma Drug Is Beating Amgen
TheStreet.com
Celgene
Multiple Myeloma
Amgen
Kyprolis
Pomalyst
Flag link:
Celgene's Multiple Myeloma Powerhouse
Celgene's Multiple Myeloma Powerhouse
Motley Fool
Multiple Myeloma
Celgene
Thalomid
Revlimid
Pomalyst
Flag link:
Celgene at ASCO: Ho-Hum, Ho-Hum, and Hmmm
Celgene at ASCO: Ho-Hum, Ho-Hum, and Hmmm
Motley Fool
Celgene
ASCO
Pomalyst
Abraxane
Revlimid
Flag link:
Celgene's Rich Pipeline Offers Growth
Celgene's Rich Pipeline Offers Growth
Seeking Alpha
Celgene
Eli Lilly
Bristol-Myers Squibb
Roche
ONYX Pharmaceuticals
Pomalyst
Revlimid
Abraxane
Flag link:
Celgene And The Race To Cure Multiple Myeloma
Celgene And The Race To Cure Multiple Myeloma
Seeking Alpha
Celgene
Multiple Myeloma
Pomalyst
Flag link:
Celgene Gets OK to Sell Blood Cancer Drug
Celgene Gets OK to Sell Blood Cancer Drug
Minyanville
Celgene
Pomalyst
Multiple Myeloma
Flag link: